Radium-223 for prostate cancer shows survival benefit in study

07/17/2013 | MedPage Today (free registration)

A study published in the New England Journal of Medicine found that the alpha-emitting isotope radium-223 was linked to significantly improved survival in prostate cancer patients. The Phase III study involved 921 men with castration-resistant prostate cancer and bone metastases who did not previously undergo docetaxel therapy. The trial was stopped early after an interim analysis showed that treatment with radium-223 significantly improved survival, resulting in a median overall survival of 14.9 months among patients treated with radium-223 compared with 11.3 months for the placebo group.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX